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Table 1
Patient Characteristics
Day +1 Day +7
# Patients 83 56
Age 56 50.9
Sex 36 F, 47 M 24 F, 23 M
Race White:74 Black: 9 White: 49 Black:6
Hispanic:1
Wt 85.06 86.64
KPS 84.08 84.46
CMI 3.108 2.929
# of Prior Treatments 2.1 2.7
Multiple Myeloma 50 30
Lymphoma 30 22
Other* 3* 4
Patients Undergoing a
Second Transplant
4 4
*BuVP 2; VPCARB 1.# BCNUTHIO:2 BPCARB:1 TBICY:1
Table 2
Transplantation Data Following Engraftment
Day+1 Day+7 P Value
Transplanted
CD 34+ cells
5.024 4.018 .0617 (95% C.I. -2.062 to 0.04946)
Leukocyte
Reconstitution
ANC >500
9.9 11.43 <.0001 (95% C.I. 1.136 to 1.914)
Leukocyte
Reconstitution
ANC >1500
10.86 12.75 .0001 (95% C.I. 0.06929 to 2.096)
Platelet
Reconstitution
>20
19.48 20.61 .3577 (95% C.I. -1.298 to 3.569)
Platelet
Reconstitution
>50
21.12 21.84 .6821 (95% C.I. e2.749 to 4.118)
Length of Stay 18.16 18.91 .3982 (95% C.I. -1.006 to 2.514)
Table 3
Infection rates
Day +1 Day +7 P Value ( Fisher’s Exact Test)
Total Blood Stream
Infections (BSI)
23 14 .8453
Peripheral BSI 11 10
Line Associated BSI 12 6
UTI 19 7 .1827
Other 2* 2
*1 sputum with proteus mirabilis, 1 lesion with candida glabrata, 1 sputum
with Candida, 1 throat culture with beta hemolytic strep
Abstracts / Biol Blood Marrow Transplant 20 (2014) S104eS127 S107WA; 5 Clinical Research Division, Fred Hutchinson Cancer
Research Center (FHCRC), Seattle, WA
Purpose: Prior studies have suggested associations with
vitamin D concentrations, increased survival and prognosis
in patients with lymphoma and multiple myeloma (MM);
however little is known about patients undergoing autolo-
gous hematopoietic stem cell transplant (AHSCT). We, thus,
investigated pre-AHSCT 25-hydroxyvitamin D [25(OH)D]
concentrations and transplant related parameters to deter-
mine incidence of vitamin D insufﬁciency and overall sur-
vival in subjects diagnosed with MM and lymphoma.
Methods: An IRB approved waiver of consent retrospective
analysis was performed at Seattle Cancer Care Alliance
(SCCA) in Seattle, Washington. Retrospective data, from May
2009 and May 2010, were collected from the electronic
medical records of AHSCT adults (n¼132) diagnosed with
MM (n¼70) and lymphoma (n¼62). Variables collected
included mean pre-AHSCT total 25(OH)D concentrations,
age, gender, race, ethnicity, geographic residence, body mass
index (BMI), vitamin D-containing supplement use, date of
death, and date of last contact.
Results: The majority of both male and female subjects were
>50 years old, white and non-Hispanic/Latino, overweight or
obese, living above the 37th parallel, and reported the use of a
vitamin D-containing supplement. Age was positively asso-
ciated to disease (p¼ .002, t-test), whereas other parameters
were not. Mean pre-transplant 25(OH)D concentrations of
29.0  11.0ng/mL (p ¼ <.001, t-test) suggested a signiﬁcant
incidence of vitamin D insufﬁciency in the sample. The re-
ported use of a vitamin D-containing supplement was the
only parameter signiﬁcantly associated with 25(OH)D con-
centrations (p ¼ .014). Ultimately, pre-transplant vitamin D
status (insufﬁcient vs sufﬁcient) had no signiﬁcant impact on
overall survival in subject’s post-AHSCT [HR ¼ 0.99 (95% CI
0.45-2.20) Log-rank p¼ .997].
Conclusion: The majority of lymphoma and MM patients
have insufﬁcient pre-AHSCT 25(OH)D concentrations. In
contrast to prior studies, no association of 25(OH)D and
survival was observed. These ﬁndings support a rationale to
continue this investigation in a larger prospective sample.
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Background: Giving Filgrastim (G-CSF) following high dose
chemotherapy and autologous stem cell reinfusion (HSCT) is
routinely used to shorten duration of neutropenia and
decrease risk of infection. The optimal post-transplant day of
initiation of G-CSF is not standardized. We recently studied a
change from initiation of G-CSF from day +1 to day +7 in light
of recent data showing equivocal results.
Methods: Beginning November 1st, 2012 a control group
consisting of 83 patients with multiple myeloma or lym-
phoma undergoing autologous HSCT received G-CSF subcu-
taneously daily from Day+1 until absolute neutrophil count
(ANC) of 1500 for two consecutive days. Beginning February
1st, 2013 we evaluated 56 patients who received G-CSF
starting day +7 and compared time to ANC engraftment be-
tween the groups. Both groups received G-CSF to the same
ANC endpoint. Patients were matched for diagnosis, comor-
bidity index, number of prior therapies, and performancestatus. Additional endpoints included incidence of infection,
transfusion support, and length of stay.
Results: 83 patients in the control group received G-CSF
beginning day +1, and 56 study group patients received G-
CSF beginning day +7. There was a signiﬁcant difference in
ANC recovery both to >500 and >1500 between the groups.
On average, patients who received G-CSF starting Day +7
required 1.53 more days for ANC recovery >500 and 1.89
more days for ANC recovery >1500. However, there was no
statistical difference in platelet reconstitution or length of
stay.
Conclusion: Day +1 administration of G-CSF was associated
with earlier neutrophil recovery but there was no improve-
ment in incidence of infection or length of stay when
compared to administration beginning day +7.
